Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02698059
Recruitment Status : Recruiting
First Posted : March 3, 2016
Last Update Posted : April 4, 2019
Sponsor:
Information provided by (Responsible Party):
Somnics, Inc.

Tracking Information
First Submitted Date  ICMJE February 17, 2016
First Posted Date  ICMJE March 3, 2016
Last Update Posted Date April 4, 2019
Study Start Date  ICMJE January 2016
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 26, 2016)
Clinical success rate* of apnea-hypopnea index (AHI)** on the 1st Tx PSG Night when compared to the Baseline PSG Night. [ Time Frame: first treatment night ]
*Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of >50% and treated AHI <20 to the number of patients who complete the 1st Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 1st Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met. **AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02698059 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: February 26, 2016)
  • AE/SAE rate and type [ Time Frame: The whole study period through study completion; up to 8 weeks ]
    Vital signs, Physical examination (PE) findings and change of body figure indexes, Electrocardiogram (ECG) findings as reflected in polysomnography (PSG), Adverse events (AEs), Serious adverse events (SAEs), Changes in the oral and dental condition
  • Clinical success rate* of apnea-hypopnea index (AHI)** on the 2nd Tx PSG Night when compared to the 1st Tx PSG Night. [ Time Frame: second treatment night ]
    *Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of >50% and treated AHI <20 to the number of patients who complete the 2nd Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 2nd Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met. **AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep.
  • Change of Oxygen Desaturation Index (ODI)* from the Baseline PSG Night compared to the 1st Tx PSG Night and the 2nd Tx PSG Night; and the change from the 1st Tx PSG Night compared to the 2nd Tx PSG Night. [ Time Frame: At the Baseline PSG Night, the 1st Tx PSG Night and/or the 2nd Tx PSG Night ]
    *ODI is the event number of oxygen level drops by 3 percent or more from baseline divided by total sleep time (TST), i.e., the number of hours of sleep.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea
Official Title  ICMJE A Multi-center, Two-stage, Single-arm, Prospective, First-night Order Cross-over, Evaluator-blind Study to Evaluate the Efficacy, Safety and Tolerance of the iNAP® Sleep Therapy System in Adults With Obstructive Sleep Apnea (OSA)
Brief Summary This is a post-marketing surveillance study to investigate the efficacy and safety of the Negative Pressure Sleep Therapy System for the treatment of obstructive sleep apnea.
Detailed Description This is a multi-center, two-stage, single-arm, prospective, first-night order cross-over, evaluator-blind, post-marketing surveillance study to evaluate the efficacy, safety and tolerance of the iNAP® Sleep Therapy System (iNAP), a tongue and soft palate retaining intraoral device, in adults with obstructive sleep apnea (OSA).
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Obstructive Sleep Apnea (OSA)
Intervention  ICMJE Device: iNAP® Sleep Therapy System (iNAP)
The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
Study Arms  ICMJE
  • Experimental: Treated
    iNAP® Sleep Therapy System Treatment
    Intervention: Device: iNAP® Sleep Therapy System (iNAP)
  • No Intervention: Baseline/Control
    Self-controlled, pre-treatment baseline
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 26, 2016)
63
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 2020
Estimated Primary Completion Date December 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • 1) Female or male adults with age between 18~65 years old. (S1)
  • 2) Non-obese patients with body mass index (BMI) <29 kg/m2. (S1)
  • 3) Patients able to read and sign on the informed consent form and able to comply with study requirements. (S1)
  • 4) Patients able to be properly fitted* with the oral interface as observed by the device feasibility test. (S1)
  • 5) Patients with oxygen desaturation index (ODI) between 10~40 (S2).
  • 6) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and total sleep time (TST) ≥4 hours/night (S3).

    • iNAP® pressure more negative than -30 mmHg will be considered evidence of effective oral appliance application.
  • 7) Patients with apnea-hypopnea index (AHI) between 10~40 and TST ≥4 hours/night (Baseline PSG Night).
  • 8) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and TST ≥4 hours/night (1st Tx PSG Night).

    • iNAP® pressure more negative than -30 mmHg will be considered evidence of effective oral appliance application.

Exclusion Criteria:

  • 1) Patients who are allergic to silicone.
  • 2) Patients with obstructed nasal passages as evidenced by the inability to breathe through the nose with the mouth closed.
  • 3) Patients who recently experienced a near-miss or prior automobile accident due to sleepiness.
  • 4) Patients who have or have had hypoxemia (SpO2 <80%) in the past six months caused by diseases other than OSA such as cardiac disease or severe pulmonary/respiratory disorders such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, pneumothorax, pneumonia, etc.
  • 5) Female patients who are lactating, pregnant or intend to become pregnant during the study period.
  • 6) Patients with primary insomnia or any concomitant diagnosed or suspected sleep disorder.
  • 7) Patients with muscle disease, central nervous disease or chronic neurological disorders, including central sleep apnea*.

    • Central sleep apnea is defined as a central apnea index (CAI) ≥ 5/hr or if central sleep apnea accounts for ≥ 50% of the total AHI.
  • 8) Patients in whom it is not suitable to use iNAP® in the opinion of the Investigator including, but not limited to, alcohol or substance abuse, loose teeth, missing teeth, or grinding teeth, completed deviated septum (Type IV or VII) or completed closed nostrils or advanced periodontal disease or tonsillar volumes greater than grade 3.
  • 9) Patients with an inability to sleep through the night including, but not limited to, menopausal hot flashes, working at nights or rotating night shifts, planned travel across four or more time zones during the study period or within one week prior to study participation, or a sleep schedule not compatible with study site practices.
  • 10) Patients with potential complications of sleep apnea that, in the opinion of the Investigator, may affect the study interpretation or the health or safety of the patients including, but not limited to, narcolepsy, restless leg syndrome, nasopharyngeal carcinoma (NPC), end stage renal failure, a history of severe cardiovascular disease (including New York Heart Association (NYHA) class III or IV cardiac failure, coronary artery disease with angina or myocardial infarction/stroke in the past six months, uncontrolled hypertension or hypotension or cardiac arrhythmias), unstable heart or renal transplantation or use of medicine or other treatment(s) that may confound the result of the study or pose additional risks to the patient, such as oral anticoagulants or other agents making patients prone to tongue hemorrhage.

Stage II Inclusion Criteria:

Patients who fulfill all the enrollment criteria of Stage I and whose treated AHI on the 1st Tx PSG Night is below 40.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: C.C. Chen, Ph.D. chungchu1@somnics.com
Contact: C.N. Huang, Ph.D. huangcn@somnics.com
Listed Location Countries  ICMJE Germany,   Taiwan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02698059
Other Study ID Numbers  ICMJE iNAP®-CE-1501
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Somnics, Inc.
Study Sponsor  ICMJE Somnics, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Hartmut Schneider, M.D. American Sleep Clinic Frankfurt
PRS Account Somnics, Inc.
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP